01—Abstract
Summary
Summary of the 8-K filed February 6, 2024. Cited figures are marked; the original filing is the authoritative source.
Royalty Pharma plc (RPRX) filed this Form 8-K under Item 8.01 (Other Events) to disclose its financial exposure to MorphoSys AG following an agreement announced February 5, 2024, under which Novartis would acquire MorphoSys for €68 per share.
Royalty Pharma's July 2021 strategic funding partnership with MorphoSys committed up to $2.025 billiona to enable MorphoSys's acquisition of Constellation Pharmaceuticals, in exchange for royalties, development funding bonds and equity. Royalty Pharma holds royalties on four therapies: a 3% royalty on future net sales of pelabresib (myelofibrosis, with an NDA expected mid-2024 based on the phase 3 MANIFEST-2 study), a 3% royalty on tulmimetostat (phase 2 EZH2 inhibitor), a tiered mid-single digit royalty on Tremfya (marketed by Johnson and Johnson, which generated $3.1 billion in 2023 sales), and a tiered 3.3% to 4.2% effective royalty on trontinemab (Alzheimer's, in development by Roche). The company provided $300 million in exchange for Development Funding Bonds, which MorphoSys will repay through 36 consecutive payments totaling approximately $660 million (2.2 times the funded amount), beginning in the fourth quarter of 2024.
Royalty Pharma also acquired 1,337,552 MorphoSys shares, which the filing states would be worth approximately $100 millionb at the proposed Novartis acquisition price and current exchange rates. The acquisition would therefore likely accelerate realization of Royalty Pharma's MorphoSys-related investments, though the filing does not state the timing or terms of any such payoff.
02—Key points
Key Highlights
- Royalty Pharma's MorphoSys exposure includes up to $2.025 billion in committed funding under the July 2021 partnership.
- Novartis agreed to acquire MorphoSys for €68 per share, announced February 5, 2024.
- Development Funding Bonds: $300 million provided, to be repaid with about $660 million over 36 consecutive payments starting Q4 2024.
- Royalties include 3% on pelabresib (NDA expected mid-2024 in US and EU) and 3% on tulmimetostat (phase 2).
- Royalty Pharma holds a tiered mid-single digit royalty on Tremfya, which generated $3.1 billion in 2023 sales per the filing.
- Royalty Pharma's trontinemab royalty is tiered at 3.3% to 4.2% effective, with Roche developing the Alzheimer's therapy.
- Royalty Pharma owns 1,337,552 MorphoSys shares, valued at roughly $100 million at the proposed acquisition price.
03—Questions
Frequently Asked Questions
How much has Royalty Pharma committed to MorphoSys?
Under its July 2021 strategic funding partnership, Royalty Pharma committed up to $2.025 billion to fund MorphoSys's acquisition of Constellation Pharmaceuticals, in exchange for royalties, development funding bonds and equity.
What does Royalty Pharma receive from the Development Funding Bonds?
Royalty Pharma provided $300 million for the bonds. MorphoSys will make 36 consecutive payments totaling approximately $660 million, which the filing describes as 2.2 times the funded amount, beginning in the fourth quarter of 2024.
What royalties does Royalty Pharma hold on MorphoSys-related therapies?
It holds a 3% royalty on pelabresib and a 3% royalty on tulmimetostat, both from MorphoSys. It also holds a tiered mid-single digit royalty on Tremfya, marketed by Johnson and Johnson, and a tiered 3.3% to 4.2% effective royalty on trontinemab, which Roche is developing.
What is the value of Royalty Pharma's MorphoSys shares?
Royalty Pharma acquired 1,337,552 MorphoSys shares, which the filing states would be worth approximately $100 million at Novartis's proposed acquisition price and current foreign exchange rates.
When is pelabresib expected to be submitted for regulatory approval?
A New Drug Application for pelabresib is expected to be submitted in the United States and European Union in mid-2024, based on the results of the phase 3 MANIFEST-2 study.
04—Continue